Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Postmenopausal Women Clear all

Conditions: Mammographic Breast Density
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Osteoporosis
Interventions: letrozole, zoledronic acid; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Normal Hepatic Function, Impaired Hepatic Function
Interventions: LDE225; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Musculoskeletal Diseases
Interventions: ACE-083; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Homeostasis, Bone and Bones
Interventions: Dexlansoprazole, Esomeprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 75 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more

Conditions: Healthy
Interventions: Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Relugolix/E2/NETA FDC, Relugolix, Erythromycin; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Osteoporosis
Interventions: SB-751689; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 65 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer, Endometrial Cancer
Interventions: Genistein, Placebo; Dietary Supplement
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Menopause, Cardiovascular Risk Factor
Interventions: L-Citrulline, Placebo, Glutathione; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years to 79 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Healthy Postmenopausal Women
Interventions: T121, Zoledronic acid; Drug
Lead sponsor: Thar Pharmaceuticals, Inc; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: Mylan Estradiol Transdermal System 0.025 mg/day, Climara® Transdermal System 0.025 mg/day; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 69 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Menopause, Healthy Female Participants
Interventions: Estradiol/Levonorgestrel Transdermal System; Drug
Lead sponsor: Corium Innovations, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Effect of Hepatic Impairment on LDE225..

Phase 1 Study of ACE-083 in Healthy Subjects

Effect of Dexlansoprazole on Bone Homeostasis

Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects